

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC. and APOTEX CORP.

Petitioners

V.

ELI LILLY & COMPANY

Patent Owner

U.S. Patent No. 7,772,209

Filed: July 11, 2007

Issued: August 10, 2010

Inventor: Clet Niyikiza

TITLE: ANTIFOLATE COMBINATION THERAPIES

Inter Partes Review No.: IPR2016-01191

UPDATED MANDATORY NOTICE

Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioners Apotex Inc. and Apotex Corp. (“Apotex”), hereby submit this Updated Mandatory Notice of related matters per 37 C.F.R. § 42.8(b)(2), to supplement the notice of related matters in the Petition:

- *Petition for IPR by Teva Pharmaceuticals USA, Inc.*, PTAB-IPR2016-01340 (filed July 1, 2016);
- *Petition for IPR by Teva Pharmaceuticals USA, Inc.*, PTAB-IPR2016-01341 (filed July 1, 2016); and
- *Petition for IPR by Teva Pharmaceuticals USA, Inc.*, PTAB-IPR2016-01343 (filed July 1, 2016).

Respectfully submitted,

July 8, 2016

/John D. Polivick/

John D. Polivick (Reg. No. 57,926)

jpolivick@rmmslegal.com

Rakoczy Molino Mazzochi Siwik LLP

6 West Hubbard Street, Suite 500,

Chicago, Illinois 60654

Tel. 312-222-5127

CERTIFICATE OF SERVICE

I hereby certify that on July 8, 2016, a copy of this Updated Mandatory Notice was served via U.S.P.S. Priority Mail Express, upon the following:

Elizabeth A. McGraw
Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

And electronically on:

Dov P. Grossman
Williams & Connolly, LLP
725 12th St., NW
Washington, DC 20005

dgrossman@wc.com
dkrinsky@wc.com
leeds_james@lilly.com

Lead Counsel for Eli Lilly & Company in IPR2016-00240

Dated: July 8, 2016

/John D. Polivick/
Telephone: (312) 222-6305
Facsimile: (312) 222-6325